Cargando…

Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review

Chronic lymphocytic leukemia (CLL), which is the most common type of leukemia in western countries in adults, is characterized by heterogeneity in clinical course, prognosis and response to the treatment. Although, in recent years a number of factors with probable prognostic value in CLL have been i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stefaniuk, Paulina, Onyszczuk, Julia, Szymczyk, Agnieszka, Podhorecka, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886107/ https://www.ncbi.nlm.nih.gov/pubmed/33603488 http://dx.doi.org/10.2147/CMAR.S283903

Ejemplares similares

The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review
por: Stefaniuk, Paulina, et al.
Publicado: (2020)

In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge
por: Stefaniuk, Paulina, et al.
Publicado: (2022)

Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2016)

Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients
por: Szymczyk, Agnieszka, et al.
Publicado: (2019)

Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease
por: Szymczyk, Agnieszka, et al.
Publicado: (2018)

Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2015)

Telomere status in chronic lymphocytic leukemia with TP53 disruption
por: Guièze, Romain, et al.
Publicado: (2016)

The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2015)

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes
por: Nguyen-Khac, Florence
Publicado: (2022)

Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion
por: Gupta, A, et al.
Publicado: (2015)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Impact Of TP53 Gene Promoter Methylation On Chronic Lymphocytic Leukemia Pathogenesis And Progression
por: Saeed, Waleed Haji, et al.
Publicado: (2019)

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
por: Quijada‐Álamo, Miguel, et al.
Publicado: (2021)

Abnormal microRNA expression in the course of hematological malignancies
por: Szymczyk, Agnieszka, et al.
Publicado: (2018)

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
por: Malcikova, J, et al.
Publicado: (2015)

TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing
por: Minervini, Crescenzio Francesco, et al.
Publicado: (2016)

Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases
por: Soussi, Thierry, et al.
Publicado: (2022)

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
por: Cafforio, Luciana, et al.
Publicado: (2021)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2010)

Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
por: Podhorecka, Monika, et al.
Publicado: (2017)

Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment
por: Brieghel, Christian, et al.
Publicado: (2019)

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones
por: Carrà, Giovanna, et al.
Publicado: (2017)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
por: Malcikova, J., et al.
Publicado: (2018)

TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype
por: Ramos-Campoy, Silvia, et al.
Publicado: (2022)

The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study
por: De Luca, Giuseppa, et al.
Publicado: (2022)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells
por: Podhorecka, Monika, et al.
Publicado: (2010)

HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
por: Blanco, Gonzalo, et al.
Publicado: (2016)

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
por: Puiggros, Anna, et al.
Publicado: (2017)

Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods
por: Chauffaille, Maria de Lourdes L.F., et al.
Publicado: (2020)

B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities
por: Kluckova, Katarina, et al.
Publicado: (2022)

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia
por: Chitadze, Guranda, et al.
Publicado: (2023)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1p51f5b9o8aa6hmu5cnssat72